Lighthouse Financial LLC Purchases New Stake in Eli Lilly and Company (NYSE:LLY)

Lighthouse Financial LLC bought a new stake in shares of Eli Lilly and Company (NYSE:LLY - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,341 shares of the company's stock, valued at approximately $3,351,000. Eli Lilly and Company accounts for 2.7% of Lighthouse Financial LLC's portfolio, making the stock its 10th largest holding.

Several other hedge funds and other institutional investors have also bought and sold shares of LLY. Alpha Wealth Funds LLC purchased a new stake in shares of Eli Lilly and Company during the 4th quarter valued at about $477,000. IronOak Wealth LLC. purchased a new stake in Eli Lilly and Company in the 4th quarter worth approximately $1,308,000. Wood Tarver Financial Group LLC bought a new position in Eli Lilly and Company in the 4th quarter worth approximately $480,000. TFR Capital LLC. bought a new position in shares of Eli Lilly and Company during the 4th quarter valued at approximately $3,158,000. Finally, Castle Rock Wealth Management LLC boosted its position in shares of Eli Lilly and Company by 2.5% during the 4th quarter. Castle Rock Wealth Management LLC now owns 2,975 shares of the company's stock valued at $2,512,000 after acquiring an additional 73 shares during the last quarter. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Stock Up 0.2%

Eli Lilly and Company stock traded up $1.52 during mid-day trading on Thursday, hitting $720.91. The company had a trading volume of 2,785,058 shares, compared to its average volume of 3,626,567. The stock has a market cap of $683.24 billion, a price-to-earnings ratio of 61.56, a PEG ratio of 1.40 and a beta of 0.48. Eli Lilly and Company has a 1 year low of $677.09 and a 1 year high of $972.53. The company has a quick ratio of 0.97, a current ratio of 1.15 and a debt-to-equity ratio of 2.00. The business has a fifty day moving average of $782.03 and a 200 day moving average of $801.29.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last announced its earnings results on Thursday, May 1st. The company reported $3.34 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $4.64 by ($1.30). The business had revenue of $12.73 billion for the quarter, compared to analysts' expectations of $12.77 billion. Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. The business's revenue was up 45.2% on a year-over-year basis. During the same quarter last year, the business posted $2.58 earnings per share. On average, sell-side analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 10th. Investors of record on Friday, May 16th will be given a $1.50 dividend. The ex-dividend date is Friday, May 16th. This represents a $6.00 dividend on an annualized basis and a yield of 0.83%. Eli Lilly and Company's dividend payout ratio (DPR) is 48.82%.

Insider Activity at Eli Lilly and Company

In other news, CAO Donald A. Zakrowski sold 1,000 shares of Eli Lilly and Company stock in a transaction on Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the completion of the transaction, the chief accounting officer now owns 5,840 shares of the company's stock, valued at $4,778,521.60. The trade was a 14.62% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. 0.13% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on LLY. Truist Financial raised their price target on Eli Lilly and Company from $1,029.00 to $1,038.00 and gave the stock a "buy" rating in a research report on Monday, February 3rd. Guggenheim reissued a "buy" rating on shares of Eli Lilly and Company in a report on Friday, May 23rd. The Goldman Sachs Group raised Eli Lilly and Company from a "neutral" rating to a "buy" rating and lowered their price target for the stock from $892.00 to $888.00 in a report on Tuesday, April 8th. HSBC downgraded Eli Lilly and Company from a "buy" rating to a "reduce" rating and decreased their target price for the stock from $1,150.00 to $700.00 in a report on Monday, April 28th. Finally, Cantor Fitzgerald assumed coverage on Eli Lilly and Company in a report on Tuesday, April 22nd. They issued an "overweight" rating and a $975.00 price target for the company. One investment analyst has rated the stock with a sell rating, two have assigned a hold rating and eighteen have issued a buy rating to the company. According to MarketBeat, Eli Lilly and Company presently has a consensus rating of "Moderate Buy" and an average target price of $1,011.37.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.